Podcasts about tricuspid

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies All you need to know about omega-3 fatty acids Lead induced tricuspid regurgitation MythBusters: Pomegranates are heart-healthy Host: Rick Grobbee Guests: Carlos Aguiar, Martin Andreas, Deepak Bhatt Want to watch that episode? Go to: https://esc365.escardio.org/event/1150 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Martin Andreas has declared to have potential conflicts of interest to report: proctor/speaker/consultant (Edwards, Abbott, Medtronic, Boston, Braun, Zoll) and institutional Research Grants (Edwards, Abbott, Medtronic, LSI). Deepak Bhatt has declared to have potential conflicts of interest to report: research funding from Amarin paid to Brigham and Women's Hospital and the Icahn School of Medicine at Mount Sinai for my role as Principal Investigator of REDUCE-IT. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

TRIO Score and Choosing Patients Most Likely to Benefit From Tricuspid Valve Intervention Guest: Sorin V. Pislaru, M.D., Ph.D. Hosts: Sharonne N. Hayes, M.D. Tricuspid Regurgitation (TR) is an extraordinarily heterogeneous, highly prevalent valvular heart disease. Given the tremendous variability, individualizing risk in patients with TR to guide appropriate therapy will be explored. Other topics discussed will be the use of TRIO scores, GDMT as a first line in therapy, as well as when to consider surgery or percutaneous interventions.   Topics Discussed: Is TR a relevant valvular heart disease? Why the need for a risk score? So what is the TRIO score What else did you learn from the score? The future?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Commentary by Dr. Valentin Fuster

·       Nascentmc.com for medical writing assistance for your company.Visit nascentmc.com/podcast for full show notes Cilta-cel for Myeloma: The FDA approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for adults with relapsed or refractory multiple myeloma who have tried at least one prior therapy including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. This CAR T-cell therapy, initially approved in 2022, was confirmed effective in the phase 3 CARTITUDE-4 study, showing significant reduction in disease progression or death risk by 59% compared to standard care. Enhertu for HER2-positive Solid Tumors: Fam-trastuzumab deruxtecan-nxki (Enhertu) received FDA approval for treating unresectable or metastatic HER2-positive solid tumors in adults who have had previous systemic treatment and lack satisfactory alternative options. This therapy, a conjugate of an anti-HER2 antibody and a cytotoxic drug, was first approved in 2019 and targets HER2-expressing cancer cells to potentially minimize damage to normal tissues. Fanapt for Bipolar: Iloperidone (Fanapt) has been approved for the acute treatment of manic or mixed episodes in adults with bipolar I disorder. Previously approved for schizophrenia, iloperidone targets neurotransmitters like dopamine and serotonin. It demonstrated efficacy in a pivotal trial, showing significant improvement on the Young Mania Rating Scale. Zevtera for Multiple Bacterial Infections: Ceftobiprole medocaril sodium (Zevtera) was approved for treating adults with Staphylococcus aureus bloodstream infections, right-sided infective endocarditis, and acute bacterial skin and skin structure infections. Also approved for pediatric community-acquired bacterial pneumonia, ceftobiprole is a broad-spectrum cephalosporin that combats various bacteria including MRSA. TriClip for Tricuspid Regurgitation: The FDA approved the TriClip™ transcatheter edge-to-edge repair system for treating tricuspid regurgitation. This minimally invasive option clips the tricuspid valve leaflets to improve blood flow and prevent the need for surgery. The TRILUMINATE Pivotal trial showed significant improvements in TR severity and quality of life with a good safety profile. Revumenib for Acute Leukemia: The FDA granted priority review to revumenib (SNDX-5613) for treating adult and pediatric patients with relapsed or refractory acute leukemia with KMT2A rearrangements. As a new therapeutic agent, revumenib inhibits the menin-MLL protein interaction crucial in leukemic transformation. Early trial results show promising remission rates, with a PDUFA action date scheduled for September 26, 2024.  

Commentary by Dr. Valentin Fuster

Tricuspid Valve Repair (congenital and acquired) Guest: Joseph A. Dearani, M.D. Hosts: Paul A. Friedman, M.D. Tricuspid regurgitation is being recognized with increased frequency in the current era. The etiology ranges from congenital anomalies and acquired diseases. The most common causes are typically functional tricuspid regurgitation secondary to left-sided heart disease, atrial fibrillation with right heart dilatation, and pacemaker/ICD lead-induced.   Topics Discussed: Most common causes of tricuspid regurgitation (acquired and congenital) Is the risk of tricuspid valve surgery high? Which is more common: isolated tricuspid valve surgery vs concomitant tricuspid valve surgery? Are there minimally invasive approaches to tricuspid valve operation? Do all surgeons perform tricuspid valve repair? What are the most common concomitant procedures with tricuspid valve surgery? (maze, LA appendage closure, etc.) Is pulmonary hypertension a contraindication to tricuspid valve surgery? Does liver dysfunction improve following tricuspid valve surgery. What is the role of percutaneous therapy for tricuspid valve disease? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

`    Free course on ChatGPT4 in medical writing and editing at learnAMAstyle.com ·       Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Lifileucel for Melanoma: Lifileucel (Amtagvi) has received accelerated FDA approval for unresectable metastatic melanoma in adults previously treated with specific inhibitors, marking it as the first FDA-approved T cell therapy for solid tumor cancer. The therapy involves collecting and expanding a patient's own T cells from their tumor for reinfusion, demonstrating a 31.5% objective response rate in a global study. A phase 3 trial is in progress to confirm its clinical benefit. Iloprost Injection for Frostbite: The FDA approved Aurlumyn (iloprost) injection, the first-ever treatment for severe frostbite in adults to reduce amputation risk. Iloprost, a vasodilator, showed effectiveness in an open-label trial of 47 adults, offering a significant advancement in managing severe frostbite. MDMA-Assisted Therapy for PTSD: The FDA is considering a new drug application for MDMA-assisted psychotherapy for PTSD, a potential first federal approval of its kind. Supported by two Phase 3 clinical trials showing safety and efficacy, this therapy represents a novel treatment avenue for severe PTSD. NALIRIFOX for Pancreatic Cancer: NALIRIFOX, a combination chemotherapy regimen, has been approved as a first-line treatment for metastatic pancreatic cancer, the first such approval in over a decade. Demonstrating a survival benefit in phase 3 trials, NALIRIFOX offers a new standard for previously untreated patients. Tepotinib for NSCLC: The FDA has fully approved tepotinib (Tepmetko) for NSCLC with MET exon 14 skipping alterations, following accelerated approval in 2021. The approval is based on significant response rates and median overall survival benefits shown in the VISION trial. Omalizumab for Food Allergies: Omalizumab (Xolair) injection is the first FDA-approved medication to reduce the severity of allergic reactions to multiple foods from accidental exposure. Approved for patients aged 1 year and older, it's based on phase 3 trial results showing significant efficacy in preventing reactions to common allergens. Budesonide Oral Suspension for EOE: The FDA approved budesonide oral suspension (Eohilia) as the only oral therapy for eosinophilic esophagitis in patients 11 years and older. This approval offers a specific treatment option for EoE, a chronic disease causing esophageal inflammation and related symptoms. TriClip® for Tricuspid Regurgitation: The FDA approved the TriClip™ TEER system by Abbott for minimally invasive treatment of tricuspid regurgitation, a first-of-its-kind device. Based on the TRILUMINATE trial, the TriClip showed significant improvements in patients' condition and quality of life. ACE2016 for Solid Tumors: The FDA cleared the IND application for ACE2016, an allogeneic gamma delta 2 T cell therapy targeting EGFR-expressing solid tumors. Set to begin in 2024, this Phase 1 trial will evaluate ACE2016's safety, tolerability, and pharmacodynamics. Human Acellular Vessel (HAV) for Vascular Trauma: The FDA granted Priority Review for Humacyte's BLA for the HAV for urgent arterial repair in vascular trauma cases. Supported by clinical trial and real-world evidence, the HAV offers a bioengineered alternative for arterial repair without the need for immune suppression.           Free course on ChatGPT4 in medical writing and editing at learnAMAstyle.com ·       Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes  

ChatGPT4 in medical writing and editing at learnAMAstyle.com Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Tricuspid Valve Replacement System for Tricuspid Regurgitation The FDA approved the Evoque tricuspid valve replacement system, a first in the U.S. for a transcatheter tricuspid device, after the TRISCEND II trial showed significant improvements in TR grade and patient symptoms. TR, where the heart's valve does not close properly causing blood backflow, can now be treated with this device, which also received CE Mark approval in Europe and is produced by Edwards Lifesciences. Afami-Cel for Synovial Sarcoma The FDA is prioritizing the review of afamitresgene autoleucel (afami-cel) for advanced synovial sarcoma, based on positive results from the SPEARHEAD-1 trial showing a 39% response rate and increased survival rates. Afami-cel targets MAGE-A4 in synovial sarcoma, a rare soft tissue sarcoma, offering a new treatment option for this aggressive disease. It's manufactured by Adaptimmune Therapeutics with a decision expected by August 4, 2024.  Pulsed Field Ablation for Atrial Fibrillation Boston Scientific's FARAPULSE PFA System has been FDA approved for treating intermittent atrial fibrillation, offering a non-thermal, tissue-selective ablation alternative with proven safety and efficacy. The approval was based on the ADVENT study and real-world data, highlighting shorter ablation times and no severe side effects. Boston Scientific plans an immediate U.S. launch. Shorter Turnaround Time for Axi-cel The FDA approved a manufacturing process change for axi-cel (Yescarta), reducing delivery time from 16 to 14 days, which is a CD19-directed CAR T-cell therapy for certain lymphomas. This change, granted to Kite, a Gilead Sciences subsidiary, aims to improve treatment accessibility by offering faster delivery of this personalized therapy. AI Algorithm for Cervical Cancer Screening Hologic's Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has been FDA approved, introducing the first digital cytology platform integrating AI for cervical cancer screening. This system digitizes traditional Pap test slides, applying AI to enhance detection of pre-cancerous and cancerous cells, improving sensitivity and enabling remote case review. It will be available in the U.S. in early 2024. Trastuzumab Deruxtecan for Solid Tumors The FDA granted priority review to trastuzumab deruxtecan for treating unresectable or metastatic HER2-positive solid tumors, potentially marking it as the first HER2-directed, tumor-agnostic therapy. Based on the DESTINY-PanTumor02 study, showing promising survival outcomes, a decision is expected in the second quarter of 2024. The drug is developed by AstraZeneca and Daiichi Sankyo.  

A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients with Severe Tricuspid Regurgitation: The TRISCEND II Trial

Join us for a discussion on the new data from TCT 2023 on transcatheter tricuspid valve replacement with the Columbia Structural Heart and Valve team. In this episode, delve into not only the latest findings but also the intriguing questions that arise from the groundbreaking research.

Commentary by Dr. Valentin Fuster

Join us for a discussion on the new data from TCT 2023 on transcatheter tricuspid valve replacement with the Columbia Structural Heart and Valve team. In this episode, delve into not only the latest findings but also the intriguing questions that arise from the groundbreaking research.

Quality of Life After Transcatheter Tricuspid Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results from the Randomized TRILUMINATE Pivotal Trial

Tricuspid Regurgitation: Causes and Management Guest: Mackram F. Eleid, M.D. Hosts: Paul A. Friedman, M.D. This podcast discusses emerging concepts in the management of tricuspid regurgitation and novel transcatheter therapies for tricuspid regurgitation. Topics Discussed:  The various interventional treatment strategies for tricuspid regurgitation The potential benefits of correcting tricuspid regurgitation with transcatheter repair The risks of transcatheter tricuspid regurgitation therapies Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Commentary by Dr. Candice Silversides

Tricuspid regurgitation therapy, two more left atrial appendage trials, and reflections on being too soft on medical science are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Tricuspid Regurgitation Trilogy TAVR Safe, Effective in Aortic Regurgitation https://www.medscape.com/viewarticle/997782 The TRILUMINATE Transcatheter Tricuspid Repair Trial: Positive but No Benefit? https://www.medscape.com/viewarticle/989105 Transcatheter Tricuspid Valve Repair Effective, Safe for Regurgitation: TRILUMINATE https://www.medscape.com/s/viewarticle/989103 - TRILUMINATE NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 II. LAA Occlusion Different Strengths for LAA Closure Devices? https://www.medscape.com/viewarticle/962893 - Swiss Apero – Original paper https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057859 - Swiss Apero – One-year https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067599 Peri-device Leaks After Watchman https://pubmed.ncbi.nlm.nih.gov/35902169/ TAVR With Left Atrial Appendage Occlusion Non-inferior to TAVR Plus Medical Therapy https://www.medscape.com/viewarticle/997725 - WATCH TAVR Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067312 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Download for FREE today -  special Mnemonics Cheatsheet - so you can be SURE that you have that Must Know information down:  bit.ly/nursing-memory Outline APE To Man A-Aortic P-Pulmonic E-Erbs points T-Tricuspid M-Mitral Description Aortic and Pulmonic (A&P): 2 words, 2 spaces; these coincide in that they are both in the 2nd intercostal space. A is immediately to the right of the sternum, P is immediately to the left of the sternum. Erb's point: Erb has 3 letters; you can find this point in the 3rd intercostal space (just to the left of the sternum), also the 3rd space to auscultate Tricuspid: 5th intercostal, just to the left of the sternum. Tri = 3, this is the fourth place to auscultate in the 5th intercostal space! Mitral: Mit sounds similar to mid.. Midclavicular area and straight down just below nipple line.   Another variation of this mnemonic is: All People Enjoy Time Magazine The idea is the same . . . A.P.E.T.M . . . once you nail this you will be a pro at heart assessment.

Timing of Intervention in Patients with Severe Tricuspid Regurgitation

Commentary by Dr. Valentin Fuster

Commentary by Dr. Candice Silversides

Commentary by Dr. Candice Silversides

Vi intervjuade Filip Hammaréus, AT-läkare, Jönköping & Doktorand vid Linköpings Universitet, om sin studie som visar på en viktig pusselbit att hitta olika biomarkörer för att bättre riskstratifiera olika patienter. PP-ELI-SWE-2806

Welcome back Rounds Table Listeners! We are back today with our Classic Rapid Fire Podcast! This week, Drs. Mike Fralick and Justin Boyle discuss two recent papers about the use of dupulimab in the treatment of COPD and the role of transcatheter repair in tricuspid regurgitation. Two papers, here we go! Dupilumab for COPD with ... The post Episode 66 – Biologics in COPD and Repairing Tricuspid Regurgitation first appeared on Healthy Debate. The post Episode 66 – Biologics in COPD and Repairing Tricuspid Regurgitation appeared first on Healthy Debate.

Commentary by Dr. Valentin Fuster

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Microvascular angina Minimally invasive tricuspid valve surgery Mythbusters: An apple a day keeps the doctor away Host: Rick Grobbee Guests: Volkmar Falk and Eva Prescott Want to watch that episode? Go to: https://esc365.escardio.org/event/1095   Disclaimer This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Eva Prescott have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Volkmar Falk has declared to have potential conflicts of interest to report: Medtronic GmbH, Biotronik SE & Co., Abbott GmbH & Co. KG, Boston Scientific, Edwards Lifesciences, LivaNova, Berlin Heart, Novartis Pharma GmbH, JOTEC GmbH, Zurich Heart.  Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Naomi is a young lady sharing stories about the medical world while bringing inspiration and hope to her guests and audience with the power of the light of life. The Light of Life Podcast: https://podcasts.apple.com/us/podcast/the-light-of-life/id1615132427 Instagram: https://www.instagram.com/naomidebello/ To learn more about James, visit Professor of Perseverance. You may also contact him through email, James@professorofperseverance.com or call 615 – 336 – 2181

Host: Javed Butler, MD, MBA, MPH Guest: Pedro A Villablanca Spinetto, MD A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn't show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.

Commentary by Dr. Valentin Fuster

Commentary by Drs. Julia Grapsa, Maurice Sarano, Francesco Maisano, Paul Sorajja, Nicole Karam, Alison Duncan, and Maurizio Taramasso

Commentary by Drs. Julia Grapsa, Maurice Sarano, Francesco Maisano, Paul Sorajja, Nicole Karam, Alison Duncan, and Maurizio Taramasso

Commentary by Drs. Julia Grapsa, Maurice Sarano, Francesco Maisano, Paul Sorajja, Nicole Karam, Alison Duncan, and Maurizio Taramasso

In this podcast episode, Co-Hosts Tom Salemi and Chris Newmarker review how the medtech industry is handing the current shrinking job market. They'll review this week's Newmarker's Newsmakers which includes Medtronic, Biosense Webster, Johnson & Johnson and high profile clinical meetings. Tom then interviews Mike Dineen, CEO of Tioga Cardiovascular, which is pushing the limits for heart valves. Tioga emerged from the prolific Shifamed incubator. Dineen gives history on both Shifamed and Tioga. To learn more about the FTC's review of non-competes go here. https://www.ftc.gov/news-events/news/press-releases/2023/03/ftc-extends-public-comment-period-its-proposed-rule-ban-noncompete-clauses-until-april-19 Thanks for listening to the DeviceTalks Weekly Podcast.

Commentary by Dr. Valentin Fuster

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Interventional aspects of cardiogenic shock Diagnosis and management of tricuspid regurgitation Statistics Made Easy: Type I and Type II errors and their significance Host: Susanna Price Guests: Rebecca Hahn, Nicolle Kraenkel and Holger Thiele Want to watch that episode? Go to: https://esc365.escardio.org/event/898   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.  Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests  Stephan Achenbach, Nicolle Kraenkel, Susanna Price and Holger Thiele have declared to have no potential conflicts of interest to report.   Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.  Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.  Rebecca Hahn has declared to have potential conflicts of interest to report: Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored tricuspid valve trials, for which she receives no direct industry compensation. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Tricuspid Valve Disease Guest: Juan A. Crestanello, M.D. Host: Malcolm R. Bell, M.D. Joining us today to discuss tricuspid valve disease is Juan A. Crestanello, M.D., professor of surgery and chair of cardiovascular surgery at Mayo Clinic in Rochester, Minnesota. Tune in to learn more about the surgical approach to tricuspid valve regurgitation. Specific topics discussed: What are the most common types of tricuspid valve disease? What types of tricuspid valve disease are treated with surgery? When is it time to intervene? There has been significant controversy regarding what to do with tricuspid regurgitation at the time of left sided valve surgery: what do we do at Mayo with patients who had mild, moderate, or severe tricuspid regurgitation at the time of mitral valve surgery? Do you do tricuspid valve surgery with less than moderate tricuspid regurgitation and annular dilatation? Are there any differences in outcomes between tricuspid valve repair vs replacement? Any benefit of mechanical valves? What about tricuspid valve surgery in carcinoid heart disease? How pacing leads affect the function of the tricuspid valve? How often do you see tricuspid valve disease related to pacing leads? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Aortic and Pulmonic (A&P): 2 words, 2 spaces; these coincide in that they are both in the 2nd intercostal space. A is immediately to the right of the sternum, P is immediately to the left of the sternum. Erb's point: Erb has 3 letters; you can find this point in the 3rd intercostal space (just to the left of the sternum), also the 3rd space to auscultate Tricuspid: 5th intercostal, just to the left of the sternum. Tri = 3, this is the fourth place to auscultate in the 5th intercostal space! Mitral: Mit sounds similar to mid.. Midclavicular area and straight down just below nipple line.

Commentary by Dr. Valentin Fuster

1.09 Heart Sound Locations   Cardiovascular system review for the USMLE Step 1 exam. Heart sound locations include the aortic, pulmonic, tricuspid, and mitral positions Mnemonic to remember the positions: "all physicians take money" (aortic, pulmonic, tricuspid, mitral) Aortic position: 2nd intercostal space on the right side of the chest Pulmonic position: 2nd intercostal space on the left side of the chest Tricuspid position: 5th intercostal space on the left side of the chest Mitral position: 6th intercostal space on the left side of the chest at the midclavicular line All positions are near the midline except the mitral position

Over the last decade, the tricuspid valve has transformed from being the “forgotten valve” to gaining clinical attention as the one of the next frontiers in structural heart disease. The evolving landscape of structural interventions and multimodality imaging have led to advances in the assessment and management of TR. Dr. Tom Wang discusses considerations for the evaluation and management of TR.

Tricuspid Regurgitation: What Will it Take to Improve Care? Guest: Sorin V. Pislaru, M.D., Ph.D. Host: Paul A. Friedman, M.D. (@drpaulfriedman) Joining us today to discuss tricuspid regurgitation is Paul Friedman, M.D., a professor of medicine and chair of the department of cardiology and Sorin Pislaru, M.D., a professor of medicine and chair of the division of structural heart disease at Mayo Clinic in Rochester, Minnesota. Tune in to learn why people get tricuspid regurgitation and how they present. Specific topics discussed: Why do you think care for TR needs to be improved? Medical care delivery is a complex process. Where do you start changing the current pattern? TR is very common, and in the vast majority of patients it is secondary to other conditions. Can we apply the TRIO risk score to all patients or is this too simplistic? If we refer patients earlier are there better medical / interventional options Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

The tricuspid valve ensures that blood flows from the right atrium (top) to the right ventricle (bottom). It also prevents blood from flowing backward between those two chambers. Sometimes, the tricuspid valve does not close properly and blood leaks back into the right atrium instead of going to the lungs. This is called tricuspid regurgitation. Dr. Tom Wang talks about why this happens and how to fix it.

In the cardiac lesion series, pediatric Intensivist, Dr. Laura Ortmann, describes the background of the cardiac lesion, what it looks like clinically, the most common complications post-operatively, and how the lesion is managed. In this episode, she will discuss the cardiac lesion Tricuspid Atresia. Listen in to learn more! If you plan to listen to the cardiac lesion series in order, this episode follows the Kawashima Procedure. #drortmanncicu #picu #cicu #pediatrics

$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Fetal circulatory system 2:00, Persistent fetal circulation 6:38,  Patent ductus arteriosus 8:02, Differential cyanosis 8:40, CCHD screening 9:24, Common themes 10:39, Non-cyanotic heart defects 13:26,  Ventricular septal defects 14:08, Atrial septal defects 15:35, Eisenmenger syndrome 16:28, Aortic and pulmonary stenosis 17:42, Coarctation of the aorta 18:42, Double aortic arch 19:53, Interrupted aortic arch 21:07, Cyanotic heart defects 21:34,  Tetralogy of Fallot 23:39, Transposition of the great arteries 28:03, Hypoplastic left heart syndrome 29:47, Persistent truncus arteriosus 31:09, Partial and total anomalous pulmonary venous connection 33:01, Scimitar syndrome 35:04, Tricuspid and pulmonary atresia 36:03, Prostaglandin E1 indications 36:31, DiGeorge syndrome 38:08, CHARGE syndrome 38:42, Dextrocardia 39:06, Situs inversus and total situs inversus 39:16, Ebstein anamoly 40:04, Noonan syndrome 40:34, Turner syndrome 41:11, Down syndrome 41:28, Marfan syndrome 40:52, Congenital heart blocks 43:03, Practice questions 43:27

What is tricuspid atresia? What kind of complications did Amanda Braun face over the last three decades? What surgical interventions have helped Amanda overcome her cardiac challenges?Born in 1988, Amanda Braun was diagnosed with Tricuspid Atresia, VSD, and HRHS. She had her first of 6 surgeries at 3 months old, which was a pulmonary artery banding. At 4 she developed endocarditis and had to have the PA banding redone. Amanda required no other surgeries until age 14 when she had the Glenn and Fontan done. Apart from a sternal wire removal at age 22, Amanda was well until 32 years of age, when she began to develop a range of symptoms as her heart struggled. She had a dual-lead pacemaker implanted, which was complicated and required two procedures due to her Fontan anatomy. Amanda lives in Indiana and works as a Cardiac Monitor Technician. She also runs “Amanda's Blankets” where she makes customized blankets for adults, children, babies, and pets.The program starts with us learning a bit about Amanda in Segment 1. In the second segment, we talk about complications that Amanda has had, and in the third segment, we discuss Amanda's pacemaker and future prognosis.Helpful Related Links for Listeners:Medical Monday with Greg Hummer: Devices to Help Heart Warriors in Heart Failure -https://www.buzzsprout.com/62761/10138859Continuing Education for Understanding the Liver in Fontan Patients - https://www.buzzsprout.com/62761/2654281Advancements in Understanding the Liver in Fontan Patients Part 1 - https://www.buzzsprout.com/62761/466531Advancements in Understanding the Liver in Fontan Patients Part 2 - https://www.buzzsprout.com/62761/469590Please visit our Social Media and Podcast pages:Apple Podcasts: https://itunes.apple.com/us/podcast/heart-to-heart-with-anna/id1132261435?mt=2Facebook: https://www.facebook.com/HearttoHeartwithAnna/Instagram: https://www.instagram.com/hearttoheartwithanna/MeWe: https://mewe.com/i/annajaworskiTwitter: https://twitter.com/AnnaJaworskiYouTube: https://www.youtube.com/channel/UCGPKwIU5M_YOxvtWepFR5ZwWebsite: https://www.hug-podcastnetwork.com/Music thanks to the Baby Blue Sound Collective - https://music.apple.com/us/album/home-tonight-forever/1201349904If you enjoy this program and would like to be a Patron, please check out our Patreon page: https://www.patreon.com/HeartToHeartSupport the show

Looking for more information on this topic? Check out the Cyanotic Congenital Heart Defects: Foundations and Frameworks brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/ from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.

Commentary by Dr. Adnan Kassier

Today's Audio Brick is based on the upcoming Brick 2.0: Tricuspid Regurgitation. If you're looking for supplemental information from Bricks 1.0, read up on our Valvular Heart Disease: Foundations and Frameworks Brick. As a listener of the podcast, you can take 50% off a subscription with code RXPOD. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/ from our Musculoskeletal, Skin, and Connective Tissue collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.

Dr. Sammy Elmariah, Director, Interventional Cardiology Research at Massachusetts General Hospital discusses his recent research "Transfemoral Tricuspid Valve Replacement In Patients With Tricuspid Regurgitation: 30-day Results Of The Triscend Study" which was recently presented at the 2021 American College of Cardiology's annual scientific meeting. Dr. Sammy Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. He subsequently served as Chief Medical Resident at Lankenau Hospital. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York where he also served as Chief Fellow. While a fellow, he also completed a Masters in Public Health at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital. Currently, Dr. Elmariah is an interventional cardiologist and structural heart disease specialist at the Massachusetts General Hospital and Assistant Professor of Medicine at the Harvard Medical School. In addition, he serves as the Director of Interventional Structural Heart Disease at the Boston VA Healthcare System. He is also the Associate Director of Trial Design at the Harvard Clinical Research Institute.His clinical interest is in the management of valvular heart disease, coronary artery disease, and adult congenital heart disease. He performs transcatheter valve replacement, percutaneous coronary interventions (stents), and transcatheter closure of patent foramen ovale (PFO) and atrial septal defects (ASD).Dr. Elmariah has a specific research interest in valvular heart disease. In addition to ongoing clinical investigation of valve calcification and the progression of aortic stenosis, Dr. Elmariah is evaluating the impact of transcatheter aortic valve replacement on myocardial metabolism and myocardial remodeling. Dr. Elmariah is an MGH Heart Center Hassenfeld Research Scholar and has been awarded the Jeremiah Stamler Distinguished Young Investigator Award and an American College of Cardiology Young Investigator Award. #ACC21

Common Chief Complaints Cyanosis Difficulty feeding Failure to thrive Cyanotic Heart Lesions Truncus arteriosus Aorta and pulmonary artery are fused Single vessel comes from both ventricles Transposition of great vessels Aorta comes off RIGHT ventricle Pulmonary artery comes off LEFT ventricle Tricuspid atresia Blood unable to get from right atrium to right ventricle Tetrology of […]